Jesse Singh, a director of James Hardie Industries plc, filed a Form 144 notice on November 12, 2026, disclosing a proposed sale of 25,000 shares of the company's common stock through Goldman Sachs & Co. LLC on NYSE:JHX.
Ashish Arora, an officer of Cricut, Inc., filed a Form 144 notice on November 12, 2026, disclosing a proposed sale of 210,000 shares of Class A Common Stock through Goldman Sachs & Co. LLC, with an approximate sale date of November 11, 2026.
Robert L. Reffkin, CEO and Chairman of Compass, Inc., filed a Form 144 notice on November 12, 2026, proposing the sale of 333,332 shares of Class A Common Stock on the NYSE, with the sale executed on November 11, 2026.
Investcorp Credit Management BDC, Inc. filed an 8-K on November 12, 2026, disclosing that it entered into an Agreement and Plan of Merger with BCP Investment Corporation on November 11, 2026, under which ICMB would be acquired by BCIC through a two-step merger structure.
A Form 144 notice of proposed sale was filed on November 12, 2026, by the Ruth Reffkin Family Trust Dtd 3/31/2020, disclosing plans to sell 75,720 shares of Compass, Inc. Class A Common Stock on the NYSE.
Ross Sealfon, an officer of Arxis, Inc., filed a Form 144 notice on November 12, 2026, disclosing a proposed sale of 15,000 common shares through Goldman Sachs & Co. LLC under a Rule 10b5-1 selling plan.
Focus Partners Wealth filed a Form 144 notice of proposed sale of 10,465 preferred shares of Special Opportunities Fund, Inc. on November 12, 2026, through Fidelity Brokerage Services LLC on the NYSE.
Chad Robins, an officer of Adaptive Biotechnologies Corporation, filed a Form 144 notice on November 12, 2026, proposing the sale of 73,221 shares of common stock through Goldman Sachs & Co. LLC on behalf of the Robins Nest Family Foundation.
Aktis Oncology, Inc. filed its quarterly report on Form 10-Q with the U.S. Securities and Exchange Commission on November 12, 2026, covering the fiscal quarter ended September 30, 2026, disclosing share counts, filer status, and product candidate details for its miniprotein radioconjugate pipeline.
CoreWeave, Inc. filed its quarterly report on Form 10-Q with the U.S. Securities and Exchange Commission on November 12, 2026, covering the fiscal quarter ended September 30, 2026.